Sagimet Biosciences Inc. (SGMT) is a biotechnology company focused on developing innovative therapies to address metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). Leveraging its proprietary platform, Sagimet is advancing its lead candidate, currently in clinical trials, which aims to significantly improve patient outcomes through novel mechanisms of action. With a seasoned leadership team and robust intellectual property portfolio, the company is well-positioned to capitalize on the growing market demand for effective treatments in the metabolic space, presenting a compelling opportunity for institutional investors seeking exposure to the evolving biotech landscape. Show more

155 BOVET ROAD, SAN MATEO, CA, UNITED STATES, 94402, San Mateo, CA, 94402, USA

https://www.sagimet.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

167.5M

52 Wk Range

$1.73 - $11.41

Previous Close

$5.15

Open

$5.16

Volume

649,424

Day Range

$4.97 - $5.29

Enterprise Value

50.91M

Cash

32.5M

Avg Qtr Burn

-10.18M

Insider Ownership

5.93%

Institutional Own.

42.88%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Denifanstat (ASC40) Details Acne	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat w/ Bevacizumab Details Glioblastoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat Details Metabolic-dysfunction Associated Steatohepatitis	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat Details Non-alcoholic steatohepatitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat + Resmetirom Details Metabolic Dysfunction-Associated Steatohepatitis (MASH)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TVB-3567 Details Acne	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Denifanstat Details Liver disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.